Dosing recommendations based on eGFR full text

Graph showing dosage recommendations based on eGFR.

To improve glycemic control in adults with T2DM
Recommended starting dose: 10 mg
Increase to 25 mg in patients tolerating 10 mg who require additional glycemic control
Discontinue if eGFR persistently <30 mL/min/1.73 m²

No dosage adjustments for eGFR ≥30 mL/min/1.73 m². Not recommended for use due to insufficient data for
eGFR 20 to <30 mL/min/1.73 m². Contraindicated in eGFR <20 mL/min/1.73 m².

To reduce the incidence of CV death in adults with T2DM and established CV disease as add-on combination therapy
Recommended dose: 10 mg
Discontinue if eGFR persistently <30 mL/min/1.73 m²

No dosage adjustments for eGFR ≥30 mL/min/1.73 m². Not recommended for use due to insufficient data for
eGFR 20 to <30 mL/min/1.73 m². Contraindicated in eGFR <20 mL/min/1.73 m².

For the treatment of HF in adults with HF as add-on combination therapy
Recommended dose: 10 mg

No dosage adjustments for eGFR ≥20 mL/min/1.73 m². Not recommended for use due to insufficient data for
eGFR <20 mL/min/1.73 m².

X-axis: eGFR (mL/min/1.73 m²) from 0 to 60 in increments of 10 with 20 and 30 bold.

eGFR=estimated glomerular filtration rate; T2DM=type 2 diabetes mellitus; CV=cardiovascular.

JARDIANCE®
Dosing recommendations based on eGFR full text

JARDIANCE^®¹

Monotherapy: JARDIANCE^® (empagliflozin) is indicated for use as an adjunct to diet and exercise to improve glycemic control in adult patients with T2DM for whom metformin is inappropriate due to contraindications or intolerance.

Add-on combination: JARDIANCE^® is indicated in adult patients with T2DM to improve glycemic control in combination with metformin, metformin and a sulfonylurea, pioglitazone (alone or with metformin), linagliptin and metformin, basal or prandial insulin (alone or with metformin), when metformin alone or the existing therapy listed above, along with diet and exercise, do not provide adequate glycemic control.

Add-on combination in patients with established cardiovascular disease: JARDIANCE^® is indicated as an adjunct to diet, exercise and standard care therapy to reduce the incidence of cardiovascular death in adult patients with T2DM and established cardiovascular disease.

Heart failure: JARDIANCE^® is indicated in adults as an adjunct to standard of care therapy for the treatment of chronic heart failure.

Click here for additional safety information and for a link to the Product Monograph discussing:

Contraindications in patients treated for T2DM with severe renal impairment (eGFR <20 mL/min/1.73 m²), end-stage renal disease (ESRD) and patients on dialysis
Most serious warnings and precautions regarding diabetic ketoacidosis (DKA), a serious, life-threatening condition requiring urgent hospitalization. Fatal cases of DKA have been reported in patients with T2DM treated with JARDIANCE®. JARDIANCE® is not indicated and should not be used in patients with T1DM.
Other relevant warnings and precautions regarding patients at risk for volume depletion; patients at high risk for cerebrovascular accidents; driving or operating machinery; use in situations predisposing to ketoacidosis; when reducing concomitant insulin dose; use in combination with insulin secretagogues or insulin; genital mycotic infections; urinary tract infections; necrotizing fasciitis of the perineum (Fournier’s gangrene); patients with elevated hematocrit; patients with severe hepatic impairment; serious hypersensitivity reactions; glucose in urine; renal function abnormalities; acute kidney injury; use in settings of reduced oral intake or fluid loss; and use in pregnant or nursing women, pediatrics, and geriatrics
Conditions of clinical use, adverse reactions, drug interactions and dosing instructions

The Product Monograph is also available by calling us at 1-800-263-5103 ext. 84633.

JARDIANCE^®¹

Monotherapy: JARDIANCE^® (empagliflozin) is indicated for use as an adjunct to diet and exercise to improve glycemic control in adult patients with T2DM for whom metformin is inappropriate due to contraindications or intolerance.

Add-on combination: JARDIANCE^® is indicated in adult patients with T2DM to improve glycemic control in combination with metformin, metformin and a sulfonylurea, pioglitazone (alone or with metformin), linagliptin and metformin, basal or prandial insulin (alone or with metformin), when metformin alone or the existing therapy listed above, along with diet and exercise, do not provide adequate glycemic control.

Add-on combination in patients with established cardiovascular disease: JARDIANCE^® is indicated as an adjunct to diet, exercise and standard care therapy to reduce the incidence of cardiovascular death in adult patients with T2DM and established cardiovascular disease.

Heart failure: JARDIANCE^® is indicated in adults as an adjunct to standard of care therapy for the treatment of heart failure.

Limitation of use: JARDIANCE^® is not recommended for the emergency treatment of acute heart failure.

Click here for additional safety information and for a link to the Product Monograph discussing:

Contraindications in patients treated for T2DM with severe renal impairment (eGFR <20 mL/min/1.73 m²), end-stage renal disease (ESRD) and patients on dialysis
Most serious warnings and precautions regarding diabetic ketoacidosis (DKA), a serious, life-threatening condition requiring urgent hospitalization. Fatal cases of DKA have been reported in patients with T2DM treated with JARDIANCE®. JARDIANCE® is not indicated and should not be used in patients with T1DM.
Other relevant warnings and precautions regarding patients at risk for volume depletion; patients at high risk for cerebrovascular accidents; driving or operating machinery; use in situations predisposing to ketoacidosis; when reducing concomitant insulin dose; use in combination with insulin secretagogues or insulin; genital mycotic infections; urinary tract infections; necrotizing fasciitis of the perineum (Fournier’s gangrene); patients with elevated hematocrit; patients with severe hepatic impairment; serious hypersensitivity reactions; glucose in urine; renal function abnormalities; acute kidney injury; use in settings of reduced oral intake or fluid loss; and use in pregnant or nursing women, pediatrics, and geriatrics
Conditions of clinical use, adverse reactions, drug interactions and dosing instructions

The Product Monograph is also available by calling us at 1-800-263-5103 ext. 84633.

SYNJARDY^®²

SYNJARDY^® (empagliflozin and metformin hydrochloride tablets) is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus inadequately controlled on:

metformin
sulfonylurea in combination with metformin
pioglitazone in combination with metformin
insulin in combination with metformin

In patients already being treated and achieving glycemic control with:

metformin and empagliflozin as separate tablets
sulfonylurea in combination with metformin and empagliflozin as separate tablets
pioglitazone in combination with metformin and empagliflozin as separate tablets
insulin in combination with metformin and empagliflozin as separate tablets

Please refer to the Product Monograph for contraindications, warnings, precautions, adverse reactions, interactions, dosing and conditions of clinical use. The Product Monograph is also available by calling 1-800-263-5103 ext. 84633.

T2DM=type 2 diabetes mellitus; eGFR=estimated glomerular filtration rate; T1DM=type 1 diabetes mellitus.